Biological
BNT162 Vaccine clinical trials
Also written BNT162b2 and Tozinameran.
Keep track of what changes. Save the BNT162 Vaccine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Other names
Combined with it in one product
Studies by the year they started
58 studies that test it; most in 2021 (32)
| Year | Studies |
|---|---|
| 2020 | 5 |
| 2021 | 32 |
| 2022 | 9 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 4 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
- COVID-19
- 43
Who runs them
Industry 23 · Other 35
BioNTech SE (20) · Murdoch Childrens Research Institute (5) · National Institute of Allergy and Infectious Diseases (NIAID) (4) · The University of Hong Kong (3) · Pfizer (2) · Assistance Publique - Hôpitaux de Paris (2) · Sheba Medical Center (1) · University of Michigan (1)
Often tested with
Tested in the same studies.
2019-nCoV Vaccine mRNA-1273 (12) · ChAdOx1 nCoV-19 (5) · Sinovac COVID-19 vaccine (4) · Ad26COVS1 (3) · Biological Products (1) · AS03 (1) · Elasomeran/Davesomeran (1) · Pneumococcal 20-Valent Conjugate Vaccine (1)
Studies
Open first, then newest update. How each study uses BNT162 Vaccine is read from its arms, and is right about nine times in ten.
Testing it · 58
- A Study of COVID-19 Vaccine(s) in Children and AdultsRecruitingPhase 3BioNTech SENCT07798648Written as BNT162b2
- Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant PatientsNot yet recruitingPhase 2Fred Hutchinson Cancer CenterNCT07390968Written as Tozinameran
- A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of AgeRecruitingPhase 4BioNTech SENCT07730450Written as BNT162b2 Vaccine
- Anti-viral Action Against Type 1 Diabetes AutoimmunityRecruitingPhase 4Technical University of MunichNCT06452654Written as Comirnaty Injectable Product
- mRNA Covid-19 Vaccine Immune Response Comparisons Using Different Delivery RoutesNot yet recruitingPhase 2PharmaJet, Inc.NCT06919796Written as COMIRNATY®
- A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of AgeCompletedPhase 3BioNTech SENCT07300839Written as BNT162b2 Vaccine
- A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19CompletedPhase 3BioNTech SENCT07222384Written as BNT162b2 (2025/2026 formulation)
- COVID-19 Booster Vaccine in Autoimmune Disease Non-RespondersTerminatedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT05000216Written as BNT162b2
- A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 YearsCompletedPhase 3BioNTech SENCT07069309Written as BNT162b2 (2025/2026 recommended SARS-CoV-2 strain)
- Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy ChildrenCompletedPhase 3BioNTech SENCT04816643Written as Biological/Vaccine: BNT162b2 10mcg
- Third Dose of mRNA Vaccination to Boost COVID-19 Immunity (mBoost Study)CompletedPhase 4The University of Hong KongNCT05057182Written as BNT162b2
- Randomized Trial of COVID-19 Booster Vaccinations (Cobovax Study)CompletedPhase 4The University of Hong KongNCT05057169Written as BNT162b2
- A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy IndividualsCompletedPhase 2/3BioNTech SENCT05997290Written as BNT162b2 (Omi XBB.1.5)
- Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse ReactionCompletedPhase 4University of MichiganNCT05212610Written as Pfizer-BioNTech mRNA COVID-19 vaccine
- Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy IndividualsCompletedPhase 2/3BioNTech SENCT04368728Written as BNT162b1
- Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia.CompletedPhase 3Murdoch Childrens Research InstituteNCT05265065Written as Tozinameran - Standard Dose
- Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy PopulationCompletedPhase 2BioNTech SENCT04649021Written as BNT162b2
- COVID-19 Vaccination of Immunodeficient Persons (COVAXID)CompletedPhase 4Karolinska University HospitalNCT04780659Written as Comirnaty (COVID-19, mRNA vaccine)
- To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.CompletedPhase 3BioNTech SENCT04955626Written as BNT162b2
- COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)CompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT05289037Written as BNT162b2
See all 58 studies that test BNT162 Vaccine →
Given in every arm · 4 — BNT162 Vaccine is usual care beside what is tested
- Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)CompletedPhase 4Novartis PharmaceuticalsNCT04792567Written as BNT162
- The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial DoseCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT04977479Written as Pfizer-BioNTech COVID-19 Vaccine (Comirnaty)
- A Phase I/II Study of GLB-COV2-043 as a COVID-19 Vaccine BoosterWithdrawnPhase 1/2GreenLight Biosciences, Inc.NCT05602961Written as BNT162b2/COMIRNATY®
- Safety and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S and a Booster Vaccination With a Licensed Vaccine Against COVID-19CompletedPhase 1Universitätsklinikum Hamburg-EppendorfNCT04569383Written as Comirnaty
As the comparator · 23 — what is tested is compared with BNT162 Vaccine
- A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in AdultsCompletedPhase 2CyanVac LLCNCT06742281Written as COMIRNATY®
- A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 InfectionActive, not recruitingPhase 2VaxartNCT06672055Written as COMIRNATY®
- Booster Study of PTX-COVID19-B in Adults Aged 18 Years and OlderWithdrawnPhase 3Everest Medicines (Singapore) Pte. Ltd.NCT05534048Written as Comirnaty®
- A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults.Active, not recruitingPhase 1/2SK Bioscience Co., Ltd.NCT07280858Written as Comparator (Comirnaty)
- Mix and Match of the COVID-19 Vaccine for Safety and ImmunogenicityActive, not recruitingPhase 2Canadian Immunization Research NetworkNCT04894435Written as BNT162b2
- ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2CompletedPhase 3Bavarian NordicNCT05329220Written as Comirnaty
- Phase II/III Randomized Clinical Trial of Booster Dose of COVID-19 (Recombinant, Inactivated) VaccineCompletedPhase 2/3Butantan InstituteNCT05354024Written as BNT162b2 30μg
- A Study of the Immunogenicity and Safety of SCTV01C in Population Aged ≥12 Years and Previously Vaccinated With Inactivated COVID-19 VaccineWithdrawnPhase 2Sinocelltech Ltd.NCT05239975Written as Comirnaty
- Evaluation of Safety and Immunogenicity of the Recombinant ZR202-CoV and ZR202a-CoV Vaccines in Adults.Status unknownPhase 1/2Shanghai Zerun Biotechnology Co.,LtdNCT05490108Written as Comirnaty®
- A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster VaccinesStatus unknownPhase 3Sinocelltech Ltd.NCT05323461Written as Comirnaty
- PTX-COVID19-B, an mRNA Humoral Vaccine, Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Demonstrate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B in Comparison to the Pfizer-BioNTech COVID-19 Vaccine.CompletedPhase 2Providence Therapeutics Holdings Inc.NCT05175742Written as Pfizer-BioNTech COVID-19 vaccine
- Assessing the Immunogenicity and Safety of a HIPRA's Candidate Booster Vaccination in Adults Fully Vaccinated With Adenovirus Vaccine Against COVID-19.CompletedPhase 2Hipra Scientific, S.L.UNCT05305573Written as Comirnaty (Pfizer-BioNtech) 30 ug/dose concentrate for dispersion for injection
- mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCsStatus unknownPhase 3Stemirna TherapeuticsNCT05686161Written as Pfizer(BNT162b2);SARS-Cov-2.
- Immunogenicity of Heterologous Versus Homologous Prime Boost Schedule With mRNA and Inactivated COVID-19 VaccinesCompletedPhase 3Institut Pasteur de TunisNCT05668065Written as CoronaVac/BNT162b2
- A Phase 1a Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19Status unknownPhase 1Walvax Biotechnology Co., Ltd.NCT05394012Written as Comirnaty
- Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 VaccineStatus unknownPhase 3Vaxxinity, Inc.NCT05293665Written as BNT162b2 vaccine
- A Phase 1b Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19Status unknownPhase 1Walvax Biotechnology Co., Ltd.NCT05396573Written as Comirnaty
- Homologous vs Heterologous Third Vaccination in Kidney Transplant Recipients Kidney Transplant RecipientsStatus unknownPhase 2Medical University of ViennaNCT05324319Written as BNT162B2
- A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged ≥18 YearsStatus unknownPhase 2Sinocelltech Ltd.NCT05329051Written as Comirnaty
- A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E in Population Aged ≥12 Years Previously Fully Vaccinated With Inactivated COVID-19 VaccineStatus unknownPhase 2Sinocelltech Ltd.NCT05239806Written as Comirnaty
Showing 20 of 23.
Codes
What other systems call BNT162 Vaccine · ClinicalTrials.gg INT006857
- MeSH (NLM) D000090982BNT162 VaccineConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 5085ZFP6SJTOZINAMERANConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000090982 | BNT162 Vaccine | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 5085ZFP6SJ | TOZINAMERAN | Confirmed FDA, NLM |
Also registered as abdavomeran (UNII JV8KBX6XZG), bnt-162a1 (UNII N38TVC63NU) and pidacmeran (UNII 6FH8H9CL41).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.